EUVIMEDEUVIMED entdecken
Crossref

Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy

Michelle von Locquenghien, Pascale Zwicky, Ken Xie, Diego Adhemar Jaitin, Fadi Sheban, Adam Yalin, Florian Uhlitz, Chamutal Gur, Reut Sharet Eshed, Eyal David, Kfir Mazuz, Caroline Jennings Marin und 5 weitere

Cell · 2025-12 · 188 (25) · 7099-7117.e26

DOI: 10.1016/j.cell.2025.10.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2025-12. Verfasst von Michelle von Locquenghien und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Hauptthemen laut MEDLINE: Killer Cells, Natural, Immunotherapy, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalImmunotherapyNeoplasmsT-LymphocytesTumor-Associated MacrophagesMacrophagesCytokinesMyeloid CellsAnimalsHumansMiceTumor MicroenvironmentMice, Inbred C57BLCell Line, TumorInterleukin-2FemaleReceptors, Immunologic

Stichwörter der Autor:innen

T and NK cell synergyTME-conditional IL-2TREM2cancer immunotherapycytokinesmyeloid checkpointsmyeloid-targeted immunocytokinesingle-cell genomicssynthetic immunologytumor-associated macrophagestumor-microenvironment modulation

Substanzen

CytokinesInterleukin-2Receptors, Immunologic

Autor:innen und Institutionen

  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Immunai, New York, NY 10016, USA.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Rheumatology Department, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel; Immunai, Ramat Gan 5252213, Israel.
  • Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel. Electronic address: ido.amit@weizmann.ac.il.

Förderung

  • Israel Science Foundation

Zitieren

APA

von Locquenghien, M., Zwicky, P., Xie, K., Jaitin, D. A., Sheban, F., Yalin, A., Uhlitz, F., Gur, C., Eshed, R. S., David, E., Mazuz, K., Marin, C. J., Sankar, A., Mediratta, D., Avellino, R., Weiner, A., & Amit, I. (2025). Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell, 188(25), 7099-7117.e26. https://doi.org/10.1016/j.cell.2025.10.030

Vancouver

von Locquenghien M, Zwicky P, Xie K, Jaitin DA, Sheban F, Yalin A, et al. Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell. 2025;188(25):7099-7117.e26. doi:10.1016/j.cell.2025.10.030

BibTeX
@article{vonLocquenghien2025,
  author = {von Locquenghien, Michelle and Zwicky, Pascale and Xie, Ken and Jaitin, Diego Adhemar and Sheban, Fadi and Yalin, Adam and Uhlitz, Florian and Gur, Chamutal and Eshed, Reut Sharet and David, Eyal and Mazuz, Kfir and Marin, Caroline Jennings and Sankar, Ankita and Mediratta, Devin and Avellino, Roberto and Weiner, Assaf and Amit, Ido},
  title = {Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy},
  journal = {Cell},
  year = {2025},
  volume = {188},
  number = {25},
  pages = {7099--7117.e26},
  doi = {10.1016/j.cell.2025.10.030}
}
Kostenlos starten →